Windlas Biotech Limited



Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-U74899UR2001PLC033407

August 3, 2021

To,	To,
The Chief General Manager	The Associate Vice President
Dept. of Listing Operations	MSD - Non Continuous Markets Group
BSE Limited	National Stock Exchange of India Limited
PJ Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street,	Bandra (E)
Mumbai - 400 001	Mumbai-400051

Dear Sir,

Sub: Proposed initial public offering of [•] equity shares of Rs. 5 each (the "Equity Shares") of Windlas Biotech

Limited (the "Company", and such initial public offering, the "Offer") comprising a fresh issue of up to

[•] Equity Shares aggregating up to Rs. 1,650 million by the Company and an offer for sale of up to up to

5,142,067 Equity Shares aggregating up to ₹[•] million, comprising of up to 1,136,000 Equity Shares

aggregating up to ₹[•] million by Vimla Windlass and up to 4,006,067 Equity Shares aggregating up to

₹[•] million by the Tano India Private Equity Fund II

The IPO Committee of the Company at its meetings held on August 3, 2021 and the Selling Shareholders, in consultation with the SBI Capital Markets Limited, DAM Capital Advisors Limited (*Formerly IDFC Securities Limited*) and IIFL Securities Limited ("BRLMs"), has finalized allocation of 2,618,706 Equity Shares, to Anchor Investors at Anchor Investor Allocation Price of Rs. 460/- per Equity Share (including share premium of Rs. 455/- per Equity Share) in the following manner:

Sr. No.	Name of the Anchor Investor	No. of Equity Shares allocated	% of Anchor Investor Portion	Bid price (Rs. per Equity Share)	Amount Total amount allocated (Rs.)
1	ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTICS (P.H.D) FUND	5,43,450	20.75	460	24,99,87,000
2	NIPPON INDIA EQUITY OPPORTUNITIES AIF - SCHEME 1	2,17,410	8.30	460	10,00,08,600
3	MACQUARIE FUND SOLUTIONS - MACQUARIE ASIA NEW STARS FUND	2,17,410	8.30	460	10,00,08,600
4	OPTIMIX WHOLESALE GLOBAL EMERGING MARKETS SHARE TRUST	2,17,410	8.30	460	10,00,08,600
5	INVESCO TRUSTEE PRIVATE LIMITED-A/C INVESCO INDIA SMALLCAP FUND	2,17,410	8.30	460	10,00,08,600
6	KUBER INDIA FUND	2,17,410	8.30	460	10,00,08,600
7	UTI - HEALTHCARE FUND	1,41,780	5.41	460	6,52,18,800
8	UTI SMALL CAP FUND	75,630	2.89	460	3,47,89,800
9	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES I	44,730	1.71	460	2,05,75,800
10	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES II	48,060	1.84	460	2,21,07,600
11	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES III	43,050	1.64	460	1,98,03,000

www.windlas.com

Windlas Biotech Limited



Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-U74899UR2001PLC033407

12	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES IV	30,720	1.17	460	1,41,31,200
13	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES V	11,640	0.44	460	53,54,400
14	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES VI	6,030	0.23	460	27,73,800
15	SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM TAX ADVANTAGE FUND - SERIES - III	7,260	0.28	460	33,39,600
16	SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM TAX ADVANTAGE FUND - SERIES IV	5,100	0.19	460	23,46,000
17	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES VII	20,820	0.80	460	95,77,200
18	ELARA INDIA OPPORTUNITIES FUND LIMITED	1,18,506	4.53	460	5,45,12,760
19	BNP PARIBAS ARBITRAGE - ODI	1,08,720	4.15	460	5,00,11,200
20	BNP PARIBAS ARBITRAGE	1,08,720	4.15	460	5,00,11,200
21	AVENDUS ABSOLUTE RETURN FUND	1,08,720	4.15	460	5,00,11,200
22	CANARA HSBC ORIENTAL BANK OF COMMERCE LIFE INSURANCE COMPANY LTD	1,08,720	4.15	460	5,00,11,200
	Total	26,18,706	100.00		1,20,46,04,760

Out of the total allocation of **26,18,706** Equity Shares to the Anchor Investors, 11,95,680 Equity Shares (i.e. 45.66 % of the total Anchor Investors allocation) have been allocated to 4 Mutual Funds who have applied through a total of 13 schemes. **Scheme-wise details provided in table below**:

Sr. No.	Name of the Anchor Investor	No. of Equity Shares allocated	% of Anchor Investor Portion	Bid price (Rs. per Equity Share)	Total amount allocated (Rs.)
1	ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTICS (P.H.D) FUND	5,43,450	20.75	460	24,99,87,000
2	INVESCO TRUSTEE PRIVATE LIMITED- A/C INVESCO INDIA SMALLCAP FUND	2,17,410	8.30	460	10,00,08,600
3	UTI - HEALTHCARE FUND	1,41,780	5.41	460	6,52,18,800
4	UTI SMALL CAP FUND	75,630	2.89	460	3,47,89,800
5	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES I	44,730	1.71	460	2,05,75,800
6	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES II	48,060	1.84	460	2,21,07,600
7	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES III	43,050	1.64	460	1,98,03,000

www.windlas.com

Windlas Biotech Limited



Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-U74899UR2001PLC033407

8	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES IV	30,720	1.17	460	1,41,31,200
9	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES V	11,640	0.44	460	53,54,400
10	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES VI	6,030	0.23	460	27,73,800
11	SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM TAX ADVANTAGE FUND - SERIES - III	7,260	0.28	460	33,39,600
12	SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM TAX ADVANTAGE FUND - SERIES IV	5,100	0.19	460	23,46,000
13	SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES VII	20,820	0.80	460	95,77,200
	Total	11,95,680	45.66		55,00,12,800

As per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, in case the Offer Price discovered through book building process is higher than the Anchor Investor Allocation Price, Anchor investors will be required to pay the difference by the Anchor Investor Pay-In Date as specified in the revised CAN.

Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the Red Herring Prospectus.

We request you to make the above information public by disclosing the same on your website.

Thanking You,

For and on behalf of Windlas Biotech Limited

Authorised Signatory

Name: Ananta Narayan Panda

Designation: Company Secretary and Compliance Officer

cc: Securities and Exchange Board of India

Northern Regional Office Plate-B, 8th Floor, Office Tower-1 NBCC Complex East Kidwai Nagar New Delhi 110023